RAI2 and colorectal carcinoma: Our work provides evidence that silence or down-regulation of RAI2 in colorectal cancer may contribute to aberrant activation of Wnt signaling pathway, and consequently promote chemoresistance of CRC cells to chemotherapy drugs such as oxaliplatin and fluorouracil.